Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 18,156
- Companies
- 1,062
- Drugs tracked
- 3,385
Quick answer
NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
An adaptive, randomized, double-blind, single-center, placebo-controlled first-in-human study evaluating safety, tolerability and exposure of single and multiple ascending doses of Lactobacillus expressing CXCL12 administered topically to experimentally induced skin wounds
Pharma Mar S.A.
Wound healing
1 trial -
Food effect and single- and multiple-ascending dose clinical trial of DF2755A in healthy participants
Dompe' Farmaceutici S.p.A.
interstitial cystitis/bladder pain syndrome
1 trial -
GLPG1205 single ascending doses, oral suspension
Lakefront Biotherapeutics NV
Healthy
1 trial -
GLPG1690 single ascending doses
Lakefront Biotherapeutics NV
Healthy
1 trial -
GLPG1837 single ascending doses
Lakefront Biotherapeutics NV
Healthy
1 trial -
GLPG1972 single ascending doses
Lakefront Biotherapeutics NV
Healthy
1 trial -
MK-4646 Single Ascending Dose Study and DDI in Healthy Participants
Merck Sharp and Dohme
HIV infection
1 trial -
MK-7480 Multiple Ascending Dose Study in Healthy Participants
Merck Sharp and Dohme
Non-alcoholic steatohepatitis
1 trial -
MOR106 single ascending doses, intravenous
Lakefront Biotherapeutics NV
Healthy
1 trial -
Multiple Ascending Dose Study of LY4256984 in Participants with Sporadic Amyotrophic Lateral Sclerosis
Eli Lilly Co.
Sporadic Amyotrophic Lateral Sclerosis
1 trial -
Multiple Ascending Doses of BMS-986326 in Participants with Discoid Lupus Erythematosus, Subacute Cutaneous Lupus Erythematosus, or Systemic Lupus Erythematosus
Bristol-Myers Squibb / Pfizer EEIG
Subacute Cutaneous Lupus Erythematosus, Discoid Lupus Erythematosus, Systemic Lupus Erythematosus
1 trial -
Multiple-Ascending Doses of 2-Methoxyestradiol in Healthy Non-Pregnant Female Participants.
Laboratorios Tillomed Spain S.L.U
No medical condition.
1 trial -
Phase 1 Single Ascending Doses (SAD) of M5542 in Healthy Participants
Merck Sharp and Dohme
Healthy
1 trial -
Phase 1, Randomized, Double-blind, Placebo-Controlled, First-in-Human Single Ascending Dose Study in Healthy Participants to Assess the Safety, Tolerability, and Pharmacokinetics of JNJ-95597528 and a Proof of Mechanism Study in Participants with Mild to Moderate Asthma
Janssen-Cilag International N.V.
Mild to Moderate Asthma
1 trial -
Phase I, single and multiple ascending dose, randomized, double-blind, placebo-controlled, parallel-group clinical trial to evaluate the safety, tolerability and pharmacokinetics of topical ocular administration of DS101 in healthy subjects.
Institut für biomedizinische Analytik NMR-Imaging GmbH
Diabetic retinopathy.
1 trial -
Phase I, single and multiple ascending dose, randomized, double-blind, placebo-controlled, parallel-group clinical trial to evaluate the safety, tolerability and pharmacokinetics of topical ocular administration of DS101 in healthy subjects.
Institut für biomedizinische Analytik NMR-Imaging GmbH
Diabetic retinopathy.
1 trial -
Randomized, double-blind, placebo-controlled, two-part study assessing the safety, tolerability and pharmacokinetics of BP1.7881 administered as higher doses, after single ascending doses (Part I) and multiple ascending doses (Part II), including the assessment of BP1.7881 on cardiac repolarization, in healthy subjects.
Bioprojet Pharma
Eosinophilic esophagitis
1 trial -
Safety and tolerability of single and multiple ascending doses of lunsekimig (SAR443765) in healthy participants
Sanofi Pharma Bristol-Myers Squibb
Asthma
1 trial -
Safety, pharmacokinetics and pharmacodynamics study of Leucettinib-21 in healthy subjects, Down Syndrom and Alzheimer patients
Pharma Mar S.A.
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses and Food Effect of Leucettinib-21 in Healthy Male Subjects, followed by an open single dose of Leucettinib-21 in Down Syndrome individuals, and patients with Alzheimer’s disease
1 trial -
Single Ascending Dose of SAB-176
SAB Biotherapeutics
PHA1A
1 trial -
Single and multiple ascending dose of ZP9830 in healthy participants
Zealand Pharma A/S
Autoimmune diseases
1 trial -
Single-Ascending Doses of 2-Methoxyestradiol in Healthy Non-Pregnant Female Subjects.
Laboratorios Tillomed Spain S.L.U
No medical condition.
1 trial -
TAK-438
Takeda Pharmaceuticals International AG
Ascending Single Dose Study
1 trial -
TGD001 SAD study in healthy volunteers
Pharma Mar S.A.
A Phase I randomized, double-blind, placebo-controlled study to assess the safety and pharmacokinetics of single-ascending doses of TGD001 in healthy volunteers
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources